Welcome to our dedicated page for China Sxt Pharmaceuticals SEC filings (Ticker: SXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding how much China SXT Pharmaceuticals spends on premium herbal ingredients or when executives trade their shares often means digging through dense SEC disclosures. If you’ve ever asked, “Where can I read China SXT Pharmaceuticals’ quarterly earnings report 10-Q filing?” or “How do I track China SXT Pharmaceuticals insider trading Form 4 transactions?”, this page is built for you.
Our AI-powered platform turns every new filing into plain-language insights within minutes of hitting EDGAR. Whether it’s a 10-K annual report or an unexpected 8-K about supply-chain disruptions, Stock Titan highlights the numbers that explain how advanced, fine and regular Traditional Chinese Medicine Pieces drive revenue. You’ll see China SXT Pharmaceuticals Form 4 insider transactions in real-time, side-by-side with AI commentary that flags unusual buying or selling, while our summaries point you straight to herbal sourcing risks, regulatory changes in the PRC, and margin trends across product tiers.
Still comparing documents manually? Use our quick links below to jump to the form you need and get context fast:
- 10-K – China SXT Pharmaceuticals annual report 10-K simplified with segment detail
- 10-Q – China SXT Pharmaceuticals earnings report filing analysis each quarter
- 8-K – China SXT Pharmaceuticals 8-K material events explained the same day
- Form 4 – China SXT Pharmaceuticals executive stock transactions Form 4 alerts
- DEF 14A – China SXT Pharmaceuticals proxy statement executive compensation highlights
The result is understanding China SXT Pharmaceuticals SEC documents with AI rather than hours of scrolling. Investors monitor herbal inventory write-downs, analysts forecast cash flow, and compliance teams download footnotes—all from one place. China SXT Pharmaceuticals SEC filings explained simply: clear, timely, actionable.
China SXT Pharmaceuticals filed a Form F-3 shelf registration to offer and sell up to $600,000,000 of Class A Ordinary Shares, debt securities, warrants, rights, and units, to be offered from time to time after effectiveness via methods described in future prospectus supplements.
Its Class A Ordinary Shares trade on Nasdaq as “SXTC.” On November 7, 2025, the share price was $1.3704. As of November 10, 2025, non‑affiliate holdings were 116,027,226 shares, implying a public float of approximately $159,003,711 under General Instruction I.B.1. The company states the aggregate offering price under this prospectus will not exceed $600,000,000, and if public float falls below $75 million, sales in any 12‑month period will not exceed one‑third of public float as calculated under I.B.5. During the prior 12 months, it sold approximately $29,200,000 pursuant to I.B.5.
The company intends to use net proceeds described in applicable supplements for project development, business growth, working capital, and general corporate purposes, and may use a portion for acquisitions or investments.
Singapore investor Ching Choon Hwa has filed a Schedule 13G disclosing passive ownership of 9,803,920 Class A ordinary shares of China SXT Pharmaceuticals (SXTC). The position represents 8.45 % of the company’s 116.0 million total votes outstanding as of 29 Jul 2025. The filing indicates sole voting and dispositive power over the entire stake, with no shared control and no group affiliation. The investor certifies the shares were not acquired to influence control of the issuer. Because the threshold for a 13G filing is 5 %, this disclosure makes Ching Choon Hwa one of SXTC’s largest known individual shareholders, signaling added liquidity and a potential vote bloc but no stated activist intent. No financial performance data, purchase price, or acquisition timeline is provided.
FAQ
What is the current stock price of China Sxt Pharmaceuticals (SXTC)?
What is the market cap of China Sxt Pharmaceuticals (SXTC)?
